Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2014 | Research

miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1

Authors: Chenchao Ma, Kate Nong, Bo Wu, Bo Dong, Yueqing Bai, Hongda Zhu, Weiwei Wang, Xinyu Huang, Zhou Yuan, Kaixing Ai

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2014

Abstract

Background

microRNAs (miRNAs) are a class of small non-coding RNAs that play important roles in carcinogenesis. In the present study, we investigated the effect of miR-212 on pancreatic ductal adenocarcinoma (PDAC) and its target protein.

Methods

Quantitative real-time PCR(qRT-PCR) was performed to detect the expression of miR-212 in PDAC tissues and pancreatic cancer cell lines. miR-212 mimic, miR-212 inhibitor and negative control were transfected into pancreatic cancer cells and the effect of miR-212 up-regulation and down-regulation on the proliferation, migration and invasion of cells were investigated. Furthermore, the mRNA and protein levels of Patched-1(PTCH1) were measured. Meanwhile, luciferase assays were performed to validate PTCH1 as miR-212 target in PDAC.

Results

miR-212 was up-regulated in PDAC tissues and cells.Using both gain-of function and loss-of function experiments, a pro-oncogenic function of miR-212 was demonstrated in PDAC. Moreover, up-regulated of PTCH1 could attenuate the effect induced by miR-212.

Conclusion

These data suggest that miR-212 could facilitate PDAC progression and metastasis through targeting PTCH1, implicating a novel mechanism for the progression of PDAC.

Available only for authorised users

Guled M, Knuutila S: MicroRNAs and cancer. Duodecim. 2013, 129 (16): 1661-1669.PubMed

Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004, 116 (2): 281-297.CrossRefPubMed

Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 2009, 136 (2): 215-233.PubMedCentralCrossRefPubMed

Shenouda SK, Alahari SK: MicroRNA function in cancer: oncogene or a tumor suppressor?. Cancer Metastasis Rev. 2009, 28 (3–4): 369-378.CrossRefPubMed

Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 2006, 6 (11): 857-866.CrossRefPubMed

Ma L, Weinberg RA: Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet. 2008, 24 (9): 448-456.CrossRefPubMed

Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM: Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 2014, 1845 (2): 255-265.PubMedCentralPubMed

Bracken CP, Gregory PA, Khew-Goodall Y, Goodall GJ: The role of microRNAs in metastasis and epithelial-mesenchymal transition. Cell Mol Life Sci. 2009, 66 (10): 1682-1699.CrossRefPubMed

Ma MZ, Kong X, Weng MZ, Cheng K, Gong W, Quan ZW, Peng CH: Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical significance. J Exp Clin Cancer Res. 2013, 32 (1): 71-PubMedCentralCrossRefPubMed

10.

Guan P, Yin Z, Li X, Wu W, Zhou B: Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res. 2012, 31: 54-PubMedCentralCrossRefPubMed

11.

Wang C, Zheng X, Shen C, Shi Y: MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells. J Exp Clin Cancer Res. 2012, 31: 58-PubMedCentralCrossRefPubMed

12.

Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA: MicroRNAs–the micro steering wheel of tumour metastases. Nat Rev Cancer. 2009, 9 (4): 293-302.CrossRefPubMed

13.

Li Y, Zhang D, Chen C, Ruan Z, Li Y, Huang Y: MicroRNA-212 displays tumor-promoting properties in non-small cell lung cancer cells and targets the hedgehog pathway receptor PTCH1. Mol Biol Cell. 2012, 23 (8): 1423-1434.PubMedCentralCrossRefPubMed

14.

Scapoli L, Palmieri A, Lo ML, Pezzetti F, Rubini C, Girardi A, Farinella F, Mazzotta M, Carinci F: MicroRNA expression profiling of oral carcinoma identifies new markers of tumor progression. Int J Immunopathol Pharmacol. 2010, 23 (4): 1229-1234.PubMed

15.

Liang X, Zeng J, Wang L, Fang M, Wang Q, Zhao M, Xu X, Liu Z, Li W, Liu S, Yu H, Jia J, Chen C: Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212. PLoS ONE. 2013, 8 (7): e69784-PubMedCentralCrossRefPubMed

16.

Jiping Z, Ming F, Lixiang W, Xiuming L, Yuqun S, Han Y, Zhifang L, Yundong S, Shili L, Chunyan C, Jihui J: MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2. J Cell Biochem. 2013, 114 (12): 2666-2672.CrossRefPubMed

17.

Xu L, Wang F, Xu XF, Mo WH, Xia YJ, Wan R, Wang XP, Guo CY: Down-regulation of miR-212 expression by DNA hypermethylation in human gastric cancer cells. Med Oncol. 2011, 28 (Suppl 1): S189-S196.CrossRefPubMed

18.

Meng X, Wu J, Pan C, Wang H, Ying X, Zhou Y, Yu H, Zuo Y, Pan Z, Liu RY, Huang W: Genetic and epigenetic down-regulation of microRNA-212 promotes colorectal tumor metastasis via dysregulation of MnSOD. Gastroenterology. 2013, 145 (2): 426-436.CrossRefPubMed

19.

Walter BA, Valera VA, Pinto PA, Merino MJ: Comprehensive microRNA profiling of prostate cancer. J Cancer. 2013, 4 (5): 350-357.PubMedCentralCrossRefPubMed

20.

Yamaguchi H, Kojima T, Ito T, Kimura Y, Imamura M, Son S, Koizumi J, Murata M, Nagayama M, Nobuoka T, Tanaka S, Hirata K, Sawada N: Transcriptional control of tight junction proteins via a protein kinase C signal pathway in human telomerase reverse transcriptase-transfected human pancreatic duct epithelial cells. Am J Pathol. 2010, 177 (2): 698-712.PubMedCentralCrossRefPubMed

21.

Osada H, Takahashi T: MicroRNAs in biological processes and carcinogenesis. Carcinogenesis. 2007, 28 (1): 2-12.CrossRefPubMed

22.

Park JK, Henry JC, Jiang J, Esau C, Gusev Y, Lerner MR, Postier RG, Brackett DJ, Schmittgen TD: miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun. 2011, 406 (4): 518-523.PubMedCentralCrossRefPubMed

23.

Stone DM, Hynes M, Armanini M, Swanson TA, Gu Q, Johnson RL, Scott MP, Pennica D, Goddard A, Phillips H, Noll M, Hooper JE, de Sauvage F, Rosenthal A: The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature. 1996, 384 (6605): 129-134.CrossRefPubMed

24.

Thayer SP, di Magliano MP, Heiser PW, Nielsen CM, Roberts DJ, Lauwers GY, Qi YP, Gysin S, Fernandez-del CC, Yajnik V, Antoniu B, McMahon M, Warshaw AL, Hebrok M: Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature. 2003, 425 (6960): 851-856.PubMedCentralCrossRefPubMed

25.

Jiang J, Hui CC: Hedgehog signaling in development and cancer. Dev Cell. 2008, 15 (6): 801-812.CrossRefPubMed

26.

Gao J, Li Z, Chen Z, Shao J, Zhang L, Xu G, Tu Z, Gong Y: Antisense Smo under the control of the PTCH1 promoter delivered by an adenoviral vector inhibits the growth of human pancreatic cancer. Gene Ther. 2006, 13 (22): 1587-1594.CrossRefPubMed

27.

Fu X, Wang Q, Chen X, Huang X, Cao L, Tan H, Li W, Zhang L, Bi J, Su Q, Chen L: Expression patterns and polymorphisms of PTCH in Chinese hepatocellular carcinoma patients. Exp Mol Pathol. 2008, 84 (3): 195-199.CrossRefPubMed

28.

Ishiyama A, Hibi K, Koike M, Fujiwara M, Kodera Y, Ito K, Nakao A: PTCH gene expression as a potential marker for esophageal squamous cell carcinoma. Anticancer Res. 2006, 26 (1A): 195-198.PubMed

29.

Wolf I, Bose S, Desmond JC, Lin BT, Williamson EA, Karlan BY, Koeffler HP: Unmasking of epigenetically silenced genes reveals DNA promoter methylation and reduced expression of PTCH in breast cancer. Breast Cancer Res Treat. 2007, 105 (2): 139-155.CrossRefPubMed

30.

You S, Zhou J, Chen S, Zhou P, Lv J, Han X, Sun Y: PTCH1, a receptor of Hedgehog signaling pathway, is correlated with metastatic potential of colorectal cancer. Ups J Med Sci. 2010, 115 (3): 169-175.PubMedCentralCrossRefPubMed

31.

Sheng T, Li C, Zhang X, Chi S, He N, Chen K, McCormick F, Gatalica Z, Xie J: Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004, 3: 29-PubMedCentralCrossRefPubMed

32.

Chi S, Huang S, Li C, Zhang X, He N, Bhutani MS, Jones D, Castro CY, Logrono R, Haque A, Zwischenberger J, Tyring SK, Zhang H, Xie J: Activation of the hedgehog pathway in a subset of lung cancers. Cancer Lett. 2006, 244 (1): 53-60.CrossRefPubMed

Title: miR-212 promotes pancreatic cancer cell growth and invasion by targeting the hedgehog signaling pathway receptor patched-1
Authors: Chenchao Ma
Kate Nong
Bo Wu
Bo Dong
Yueqing Bai
Hongda Zhu
Weiwei Wang
Xinyu Huang
Zhou Yuan
Kaixing Ai
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2014
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/1756-9966-33-54

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2014

Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction

The expression profile of Dopamine D2 receptor, MGMT and VEGF in different histological subtypes of pituitary adenomas: a study of 197 cases and indications for the medical therapy

Expression of RABEX-5 and its clinical significance in prostate cancer

A novel miR-219-SMC4-JAK2/Stat3 regulatory pathway in human hepatocellular carcinoma

Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma

Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer